23:13 , Sep 20, 2018 |  BC Extra  |  Company News

Opiant gets BARDA grant for intranasal opioid antagonist

HHS partnered with Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) to accelerate development of the company's OPNT003, an intranasal formulation of opioid receptor antagonist nalmefene. Under a one-year contract with HHS's Biomedical Advanced Research and Development Authority, Opiant...
00:46 , Aug 4, 2018 |  BioCentury  |  Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
18:05 , May 25, 2018 |  BioCentury  |  Finance

HKEX’s on-demand experts

The Hong Kong stock exchange is well aware its investor base is new to the high-risk, high-reward nature of its newly hatched biotech chapter and has no qualms about admitting its own lack of expertise....
15:49 , Mar 28, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling; SNPs; tissue markers Tumor expression levels of any one of 32 genes could predict survival in estrogen receptor-positive breast cancer. The protocol uses Capture Hi-C -- a method that maps transcriptional start sites...
18:00 , Mar 9, 2018 |  BC Week In Review  |  Company News

Caladrius gets late-stage cell therapy from Shire

Shire plc (LSE:SHP; NASDAQ:SHPG) granted Caladrius Biosciences Inc. (NASDAQ:CLBS) an exclusive, worldwide license to data and regulatory filings for a late-stage CD34+ cell therapy program to treat refractory angina. Shire will receive an upfront payment...
16:56 , Jan 12, 2018 |  BC Week In Review  |  Company News

Mallinckrodt divests hemostasis portfolio for $185M

In an effort to refine its pipeline, specialty pharmaceutical company Mallinckrodt plc (NYSE:MNK) sold surgical site bleeding products Preveleak Surgical Sealant and Recothrom Thrombin topical to Baxter International Inc. (NYSE:BAX). Mallinckrodt receives an upfront payment...
23:41 , Dec 12, 2017 |  BC Extra  |  Company News

Management tracks: Achaogen, Minerva

Antibacterial company Achaogen Inc. (NASDAQ:AKAO) said Kenneth Hillan will step down as CEO, effective Jan. 1. He will remain president and president of R&D. Blake Wise, who has served as president and COO, will become...
23:12 , Aug 4, 2017 |  BioCentury  |  Finance

More from less

Shire plc (LSE:SHP; NASDAQ:SHPG) could increase in value while decreasing in size, but the market isn’t convinced. Fourteen months after closing its acquisition of rare disease company Baxalta Inc., Shire is considering a flotation of its...
20:34 , Jul 14, 2017 |  BioCentury  |  Strategy

Back to Ipsen’s roots

After spending the last six years plugging revenue holes via licensing and M&A, Ipsen Group is once again on track to meet the 2020 financial targets it set at the beginning of the decade. But...
00:05 , May 20, 2017 |  BioCentury  |  Strategy

Henri: N of 1

Gaucher’s disease had swollen Brian Berman’s spleen to the size of a basketball and physicians at NIH told the three-year-old’s parents that it had to be removed. It was 1984, there was no effective treatment...